
    
      All participants will receive Fluzone vaccine during Visit 1. For subjects receiving 2 doses
      of influenza vaccine, per ACIP guidance, a second dose of Fluzone vaccine will be
      administered during Visit 2.

      Total duration of participation in the study is approximately 28 days for participants
      receiving 1 dose and 56 days for those receiving 2 doses of Fluzone vaccine.
    
  